Pharma industry asks for more clarity in tax structure

0
727
2 of 5
Use your ← → (arrow) keys to browse

“As innovator company, we look forward to this with great excitement. However, greater clarity (is needed) on what elements will be considered for preferential tax incentives, whether it will apply to outsourced R&D, etc. Incentives are also necessary to boost manufacturing capacity of APIs, rather than depend on Chinese imports,” OPPI Director General Kanchana TK told PTI.

She further said the industry is looking forward to the end of the inverted duty structure as and when GST is implemented.

“We expect that with GST, the inverted duty structure that our industry has to deal with will become a thing of the past.

2 of 5
Use your ← → (arrow) keys to browse

LEAVE A REPLY